JonesResearch initiated coverage of MindWalk (HYFT) with a Buy rating and $5 price target. MindWalk offers an end-to-end ecosystem for drug discovery, but "what sets it apart" is its Bio-Native approach, built on a proprietary database of conserved "biological fingerprints, or HYFTs" linking sequence, structure, and function, the analyst tells investor. MindWalk's capabilities span therapeutic areas as well as modalities, attracting partnerships across 19 of the top 20 pharmas in addition to chip maker AMD (AMD), the analyst added.
